Edwards Lifesciences (EW) Invested Capital (2009 - 2026)

Edwards Lifesciences has reported Invested Capital for 18 years, with the latest figure at $11.3 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 1.06% year-over-year to $11.3 billion in Q2 2026; TTM through Jun 2026 was $11.3 billion, a 1.06% increase from a year earlier, with the FY2025 full-year figure at $10.9 billion, up 2.58% from the prior year.
• Invested Capital was $11.3 billion for Q2 2026 at Edwards Lifesciences, up from $10.9 billion in the prior quarter.
• The five-year high for Invested Capital was $11.3 billion in Q2 2026, with the low at $6.4 billion in Q4 2022.
• Average Invested Capital over 5 years is $8.7 billion, with a median of $7.9 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Invested Capital fell 0.44% in 2022, then jumped 45.71% in 2024.
• Over 5 years, Invested Capital stood at $6.4 billion in 2022, then gained by 14.27% to $7.3 billion in 2023, then soared by 45.71% to $10.7 billion in 2024, then increased by 2.58% to $10.9 billion in 2025, then rose by 3.55% to $11.3 billion in 2026.
• The last three Invested Capital figures came in at $11.3 billion (Q2 2026), $10.9 billion (Q1 2026), and $10.9 billion (Q4 2025), per Business Quant data.